British drug regulators have advised doctors to limit how many anticholinergic medicines older patients take, after a safety review concluded that the evidence can neither establish nor rule out a link to dementia.
The Medicines and Healthcare products Regulatory Agency issued the guidance following a review by the Commission on Human Medicines. The review examined 17 studies. Every one of them was rated at serious or critical risk of bias.
The Commission's own conclusion is the honest headline: there remains "considerable uncertainty whether the use of bladder anticholinergics directly increases the risk of developing dementia."
Two things should be said clearly at the outset. This is a United Kingdom regulatory action, not an American one, and no United States labeling change has followed. And the advice to limit these drugs is sound regardless of how the dementia question resolves, for reasons that have nothing to do with dementia.
What the Review Found and What It Could Not
The finding is a null in the strict sense. The evidence base was too weak to support a causal conclusion in either direction.
That distinction gets lost constantly in health coverage. "Cannot confirm a link" and "no link exists" are different statements, and so are "cannot rule out a link" and "a link is proven." The review supports the first half of each pair and neither of the second halves.
The bias ratings explain why. All 17 studies were observational, and observational research on this question faces a specific problem called reverse causation. Anticholinergics for overactive bladder are prescribed for urinary symptoms, and urinary symptoms can be an early manifestation of the neurological changes that later present as dementia. When a drug is prescribed for a symptom that precedes the disease, a database analysis will find the drug and the disease traveling together whether or not the drug caused anything.
Confounding by indication compounds it. People prescribed multiple anticholinergics tend to be sicker, frailer and older than people prescribed none, and those are independent dementia risks.
None of that proves the drugs are safe. It means the study designs available cannot answer the question, which is precisely what the commission said.
Which Drugs This Is Actually About
The review examined bladder anticholinergics, the class used for overactive bladder and urge incontinence. Common examples include oxybutynin, solifenacin and tolterodine, along with darifenacin, fesoterodine, trospium and propiverine.
The broader anticholinergic category is much larger and includes some medicines people take without a prescription. First-generation antihistamines such as diphenhydramine, certain tricyclic antidepressants, some antipsychotics, some antiparkinsonian drugs and several muscle relaxants all carry anticholinergic activity. That matters because the regulator's advice concerns the total number a patient is taking, not just bladder drugs.
Anticholinergics work by blocking acetylcholine, a neurotransmitter involved in regulating heart rate, maintaining alertness, and controlling bladder activity. Blocking it in the bladder is the therapeutic goal. Blocking it in the brain is the side effect, and the brain is exactly where acetylcholine signaling is already depleted in Alzheimer's disease.
There is a further wrinkle worth naming. Overactive bladder and incontinence are themselves common in dementia, with an estimated 53 percent of people with dementia experiencing incontinence. That overlap is part of why untangling cause from consequence has proved so difficult.
Why the Advice Stands Anyway
The regulator's recommendation does not depend on the dementia question, and this is the part patients should take seriously.
The short-term effects of anticholinergic drugs in older adults are documented and immediate. They cause confusion and delirium, particularly in people already cognitively vulnerable. They cause dry mouth, constipation, blurred vision and urinary retention, which in men with prostate enlargement can precipitate an emergency. They contribute to falls, and a fall with a hip fracture in an older adult carries its own mortality.
Two further points from the regulator explain the emphasis on total burden. Taking more than one anticholinergic multiplies the risk of these effects. And the aging body clears medications more slowly, so the same dose produces higher exposure at 80 than at 50.
That is the case for the lowest dose for the shortest necessary time, and it holds whether or not these drugs cause dementia.
What the Broader Evidence Actually Shows
Honesty cuts in both directions here, and the countervailing evidence deserves stating rather than burying.
Observational research consistently finds an association. A 2024 nested case-control study using English primary care records, covering more than 170,000 people with dementia matched to more than 800,000 without, found increased dementia odds with cumulative use of oxybutynin, solifenacin and tolterodine, while finding no significant increase with darifenacin, fesoterodine, flavoxate, propiverine or trospium. A 2025 umbrella review in Molecular Psychiatry rated the evidence for an anticholinergic dementia association at moderate certainty, driven by an apparent dose-response relationship, with pooled risk ratios in the range of 1.20 to 1.46.
A dose-response gradient is one of the classical arguments for causation. It is not proof, and observational studies that share the same structural weaknesses can agree with one another while all being wrong for the same reason.
The definitive answer requires a randomized deprescribing trial, and at least one is underway. Until it reports, the accurate position is the one the commission took.
What Patients Should and Should Not Do
Nobody should stop an anticholinergic medication because of this review. Abruptly discontinuing bladder medication does not carry dangerous withdrawal, but it does mean returning symptoms, and untreated incontinence in an older adult drives falls, social withdrawal and institutionalization.
The useful action is a medication review. Ask a pharmacist or prescriber to total up the anticholinergic burden across every prescription and over-the-counter product, because the drug most likely to be overlooked is the antihistamine someone takes for sleep. Ask whether any of them can be reduced, replaced or stopped. For overactive bladder, non-drug approaches including pelvic floor training and bladder retraining are first-line, and mirabegron works through a different mechanism without anticholinergic activity.
Any new confusion, unusual drowsiness, difficulty urinating, or a fall in an older adult on these medications warrants prompt clinical attention rather than a wait-and-see approach.
What Happens Next
The MHRA advice applies to UK prescribers. American labeling has not changed, and the FDA has not announced a parallel review. The American Geriatrics Society Beers Criteria already advise against strong anticholinergics in older adults, and that guidance predates this review.
MedicalDaily will report on any FDA action and on results from randomized deprescribing trials.
The confirmed finding is that a regulatory review of 17 studies could not confirm or exclude a causal dementia link, and that all 17 carried serious or critical bias risk. The people most affected are older adults taking one or more anticholinergic drugs, particularly those on several at once. The most reasonable action is a medication review with a pharmacist, not stopping anything unilaterally. The central uncertainty is causation, which will require a randomized trial to settle.
Frequently Asked Questions
What did the review find? That the available evidence cannot confirm or exclude a causal link between bladder anticholinergics and dementia. All 17 studies carried serious or critical risk of bias.
Does this mean the drugs are safe? No. It means the question is unresolved. Observational studies consistently find an association, but cannot establish cause.
Which drugs are involved? Bladder anticholinergics including oxybutynin, solifenacin and tolterodine. The broader class includes some antihistamines, antidepressants and antipsychotics.
Should I stop my medication? No. Ask a pharmacist or prescriber to review your total anticholinergic burden and discuss alternatives.
Does this apply in the United States? The advice is from the UK regulator. US labeling has not changed, though Beers Criteria already advise caution with strong anticholinergics in older adults.
